AEON Biopharma, Inc. (NASDAQ:AEON) Sees Significant Growth in Short Interest

AEON Biopharma, Inc. (NASDAQ:AEON) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 226,400 shares, a growth of 98.2% from the September 30th total of 114,200 shares. Currently, 2.4% of the company’s shares are sold short. Based on an average daily volume of 188,200 shares, the days-to-cover ratio is presently 1.2 days. Based on an average daily volume of 188,200 shares, the days-to-cover ratio is presently 1.2 days. Currently, 2.4% of the company’s shares are sold short.

AEON Biopharma Stock Down 4.1%

AEON stock opened at $0.84 on Friday. The company has a market cap of $9.83 million, a price-to-earnings ratio of 4.69 and a beta of 0.74. The business has a fifty day simple moving average of $0.87 and a 200-day simple moving average of $0.73. AEON Biopharma has a 52 week low of $0.38 and a 52 week high of $66.74.

Wall Street Analysts Forecast Growth

Separately, Aegis restated a “buy” rating on shares of AEON Biopharma in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat.com, AEON Biopharma presently has a consensus rating of “Buy”.

Institutional Trading of AEON Biopharma

An institutional investor recently bought a new position in AEON Biopharma stock. Dauntless Investment Group LLC purchased a new position in shares of AEON Biopharma, Inc. (NASDAQ:AEON) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 1,025,000 shares of the company’s stock, valued at approximately $594,000. AEON Biopharma accounts for approximately 0.7% of Dauntless Investment Group LLC’s investment portfolio, making the stock its 18th largest position. Dauntless Investment Group LLC owned 9.73% of AEON Biopharma as of its most recent filing with the Securities and Exchange Commission. 22.78% of the stock is currently owned by institutional investors and hedge funds.

AEON Biopharma Company Profile

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder.